PL3148510T3 - Ciekła kompozycja farmaceutyczna - Google Patents

Ciekła kompozycja farmaceutyczna

Info

Publication number
PL3148510T3
PL3148510T3 PL15724974T PL15724974T PL3148510T3 PL 3148510 T3 PL3148510 T3 PL 3148510T3 PL 15724974 T PL15724974 T PL 15724974T PL 15724974 T PL15724974 T PL 15724974T PL 3148510 T3 PL3148510 T3 PL 3148510T3
Authority
PL
Poland
Prior art keywords
pharmaceutical composition
liquid pharmaceutical
liquid
composition
pharmaceutical
Prior art date
Application number
PL15724974T
Other languages
English (en)
Inventor
Gianluca Rinaldi
Silvia Fratarcangeli
Alessandra Del Rio
Original Assignee
Fresenius Kabi Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50774705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3148510(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fresenius Kabi Deutschland Gmbh filed Critical Fresenius Kabi Deutschland Gmbh
Publication of PL3148510T3 publication Critical patent/PL3148510T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL15724974T 2014-05-23 2015-05-15 Ciekła kompozycja farmaceutyczna PL3148510T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14169754.0A EP2946766B1 (en) 2014-05-23 2014-05-23 Liquid pharmaceutical composition
PCT/EP2015/060817 WO2015177058A1 (en) 2014-05-23 2015-05-15 Liquid pharmaceutical composition
EP15724974.9A EP3148510B1 (en) 2014-05-23 2015-05-15 Liquid pharmaceutical composition

Publications (1)

Publication Number Publication Date
PL3148510T3 true PL3148510T3 (pl) 2018-11-30

Family

ID=50774705

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15724974T PL3148510T3 (pl) 2014-05-23 2015-05-15 Ciekła kompozycja farmaceutyczna

Country Status (20)

Country Link
US (5) US10493152B2 (pl)
EP (5) EP2946766B1 (pl)
JP (3) JP2017516847A (pl)
CN (2) CN106659781A (pl)
AU (4) AU2015263246B2 (pl)
CA (2) CA3050875A1 (pl)
CY (1) CY1120488T1 (pl)
DE (1) DE23189888T1 (pl)
DK (3) DK3148510T3 (pl)
ES (4) ES2572919T3 (pl)
HK (1) HK1257026A1 (pl)
HR (1) HRP20181226T1 (pl)
HU (1) HUE040097T2 (pl)
IL (1) IL249117B1 (pl)
LT (1) LT3148510T (pl)
PL (1) PL3148510T3 (pl)
PT (1) PT3148510T (pl)
RS (1) RS57772B1 (pl)
SI (1) SI3148510T1 (pl)
WO (1) WO2015177058A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS55548B1 (sr) * 2014-05-23 2017-05-31 Ares Trading Sa Tečni farmaceutski sastav
EP2946767B1 (en) 2014-05-23 2016-10-05 Ares Trading S.A. Liquid pharmaceutical composition
ES2572919T3 (es) 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
EP3459527B1 (en) * 2017-09-20 2022-11-23 Tillotts Pharma Ag Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization
JP2021519757A (ja) * 2018-03-29 2021-08-12 エアウェイ・セラピューティクス・インコーポレイテッド サーファクタントタンパク質ｄ（ｓｐ−ｄ）を含む方法及び組成物
WO2020138517A1 (ko) * 2018-12-24 2020-07-02 삼성바이오에피스 주식회사 항-TNFα 항체를 포함하는 약제학적 조성물
KR20210102954A (ko) * 2019-01-11 2021-08-20 삼성바이오에피스 주식회사 항체를 포함하는 약학적 조성물, 이를 포함하는 디바이스, 및 이의 용도
CN115429751B (zh) * 2022-09-21 2023-11-17 景泽生物医药(合肥)股份有限公司 一种人重组卵泡刺激素注射剂及其制备方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6388197A (ja) * 1986-09-30 1988-04-19 Tosoh Corp モノクロナル抗体の安定化方法
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
CA2243459C (en) 1996-02-09 2002-09-17 Basf Aktiengesellschaft Human antibodies that bind human tnf.alpha.
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US5900404A (en) 1997-08-15 1999-05-04 Amgen Inc. Chemical modification of proteins to improve biocompatibility and bioactivity
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
CN1798575A (zh) 2003-04-04 2006-07-05 健泰科生物技术公司 高浓度抗体和蛋白制剂
WO2005072772A1 (en) 2004-01-30 2005-08-11 Suomen Punainen Risti Veripalvelu Pharmaceutical compositions
WO2006012500A2 (en) * 2004-07-23 2006-02-02 Genentech, Inc. Crystallization of antibodies or fragments thereof
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1871806A2 (en) 2005-03-08 2008-01-02 Pharmacia & Upjohn Company LLC ANTI-MAdCAM ANTIBODY COMPOSITIONS
WO2006131013A2 (en) 2005-06-07 2006-12-14 Esbatech Ag STABLE AND SOLUBLE ANTIBODIES INHIBITING TNFα
TWI661833B (zh) 2007-11-30 2019-06-11 百慕達商艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
US8080518B2 (en) 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
EP4104821A1 (en) 2008-10-29 2022-12-21 Ablynx N.V. Formulations of single domain antigen binding molecules
CN102281902B (zh) 2008-11-17 2013-11-13 弗·哈夫曼-拉罗切有限公司 用于减少大分子在生理条件下聚集的方法和制剂
JP2012526121A (ja) 2009-05-04 2012-10-25 アボツト・バイオテクノロジー・リミテツド ヒト抗ｔｎｆアルファ抗体の安定した高蛋白質濃度製剤
KR20120130757A (ko) * 2010-02-26 2012-12-03 노보 노르디스크 에이/에스 안정한 항체 함유 조성물
EP2542221A4 (en) 2010-03-01 2013-10-23 Cytodyn Inc CONCENTRATED PROTEIN FORMULATIONS AND USES THEREOF
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
ES2722201T3 (es) 2010-03-22 2019-08-08 Hoffmann La Roche Composiciones y procedimientos útiles para estabilizar formulaciones que contienen proteínas
EP2399604A1 (en) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
TWI606840B (zh) 2010-11-11 2017-12-01 艾伯維生物技術有限責任公司 具有增進高濃度之抗-ＴＮＦα抗體之液體調配物
EP2471554A1 (en) 2010-12-28 2012-07-04 Hexal AG Pharmaceutical formulation comprising a biopharmaceutical drug
JP6463968B2 (ja) 2011-07-01 2019-02-06 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． アルギニンを含まない腫瘍壊死因子受容体：ｆｃ融合ポリペプチド組成物およびその使用方法
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
US10093728B2 (en) 2012-03-07 2018-10-09 Cadila Healthcare Limited Pharmaceutical formulations of TNF-alpha antibodies
JP2015519382A (ja) * 2012-06-12 2015-07-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 治療用抗体のための医薬処方物
JP6463268B2 (ja) 2012-09-07 2019-01-30 コヒラス・バイオサイエンシズ・インコーポレイテッド 安定水性アダリムマブ製剤
BR112015008186A2 (pt) 2012-10-25 2017-09-19 Medimmune Llc formulação de um anticorpo estável e de baixa viscosidade
AR093297A1 (es) * 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
EP2727602A1 (en) 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
JP6339578B2 (ja) 2012-10-31 2018-06-06 タケダ・ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ Ｇｍ−ｃｓｆ中和化合物を含む凍結乾燥製剤
SG11201503324WA (en) 2012-11-01 2015-05-28 Abbvie Inc Stable dual variable domain immunoglobulin protein formulations
CN104707146B (zh) 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
IN2014MU00610A (pl) 2014-02-21 2015-09-25 Tata Motors Ltd
IN2014MU01248A (pl) 2014-04-02 2015-10-09 Intas Pharmaceuticals Ltd
EP2946767B1 (en) 2014-05-23 2016-10-05 Ares Trading S.A. Liquid pharmaceutical composition
ES2572919T3 (es) 2014-05-23 2016-06-03 Ares Trading S.A. Composición farmacéutica líquida
RS55548B1 (sr) 2014-05-23 2017-05-31 Ares Trading Sa Tečni farmaceutski sastav
WO2017136433A1 (en) * 2016-02-03 2017-08-10 Oncobiologics, Inc. Buffer formulations for enhanced antibody stability
WO2018131893A1 (ko) 2017-01-11 2018-07-19 ㈜셀트리온 안정한 액체 제제
US20230115267A1 (en) 2020-03-13 2023-04-13 Samsung Bioepis Co., Ltd. Pharmaceutical liquid composition having increased stability

Also Published As

Publication number Publication date
DK201800070Y4 (da) 2018-12-13
WO2015177058A1 (en) 2015-11-26
EP3403646B1 (en) 2022-09-28
EP2946766B1 (en) 2016-03-02
RS57772B1 (sr) 2018-12-31
AU2020201090A1 (en) 2020-03-05
US20200085948A1 (en) 2020-03-19
US20210023215A1 (en) 2021-01-28
EP3148510A1 (en) 2017-04-05
DE23189888T1 (de) 2024-03-21
DK201800070Y8 (da) 2019-07-09
AU2015263246B2 (en) 2018-06-21
SI3148510T1 (sl) 2018-10-30
US20170189527A1 (en) 2017-07-06
AU2015263246A1 (en) 2016-11-17
US11752208B2 (en) 2023-09-12
EP2946766A1 (en) 2015-11-25
EP3659582B1 (en) 2023-08-16
DK201800071U1 (da) 2018-12-05
JP2020033361A (ja) 2020-03-05
IL249117A0 (en) 2017-01-31
US20230061801A1 (en) 2023-03-02
ES2928738T3 (es) 2022-11-22
CA2947487C (en) 2019-09-24
EP4249060A3 (en) 2024-01-03
DK201800070U1 (da) 2018-09-18
US11752209B2 (en) 2023-09-12
CA2947487A1 (en) 2015-11-26
ES2955316T3 (es) 2023-11-30
HK1257026A1 (zh) 2019-10-11
CN108785670A (zh) 2018-11-13
HRP20181226T1 (hr) 2018-10-19
CA3050875A1 (en) 2015-11-26
EP3148510B1 (en) 2018-06-27
CN106659781A (zh) 2017-05-10
LT3148510T (lt) 2018-10-10
ES2683194T3 (es) 2018-09-25
AU2020201090B2 (en) 2022-03-10
US20230338527A1 (en) 2023-10-26
JP2017516847A (ja) 2017-06-22
AU2018222887B2 (en) 2020-02-27
DK201800071Y4 (da) 2018-12-13
IL249117B1 (en) 2024-07-01
CY1120488T1 (el) 2019-07-10
EP3659582A1 (en) 2020-06-03
DK3148510T3 (en) 2018-07-16
JP2022003091A (ja) 2022-01-11
US10493152B2 (en) 2019-12-03
EP4249060A2 (en) 2023-09-27
EP3403646A1 (en) 2018-11-21
JP6962984B2 (ja) 2021-11-05
ES2572919T3 (es) 2016-06-03
AU2022203863A1 (en) 2022-06-23
US10772961B2 (en) 2020-09-15
HUE040097T2 (hu) 2019-02-28
AU2018222887A1 (en) 2018-09-13
PT3148510T (pt) 2018-09-28

Similar Documents

Publication Publication Date Title
IL282481A (en) A liquid pharmaceutical preparation
ZA201901590B (en) Liquid pharmaceutical composition
IL277241A (en) A liquid pharmaceutical preparation
ZA201901736B (en) Liquid pharmaceutical composition
HK1257026A1 (zh) 液體藥物組合物
SG11201605366QA (en) Pharmaceutical composition containing pyridylaminoacetic acidcompound
SI3206666T1 (sl) Tekoč farmacevtski sestavek, ki obsega pemetreksed
HK1244685A1 (zh) 液體藥物組合物
IL253572A0 (en) A liquid pharmaceutical preparation